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E-mail address: msudol1@geisinger.edu (M. SudolTheWWdomain-containing PQBP1 (polyglutamine tract-binding protein 1) protein regulates mRNA
processing and gene transcription. Mutations in the PQBP1 gene were reported in several X chromo-
some-linked intellectual disability (XLID) disorders, including Golabi-Ito-Hall (GIH) syndrome. The
missense mutation in the GIH syndrome maps within a functional region of the PQBP1 protein
known as the WW domain. The causative mutation of PQBP1 replaces the conserved tyrosine (Y)
at position 65 within the aromatic core of the WW domain to cysteine (C), which is a chemically sig-
niﬁcant change. In this short review, we analyze structural models of the Y65C mutated and wild
type WW domains of PQBP1 in order to infer potential molecular mechanisms that render the
mutated PQBP1 protein inactive in terms of ligand binding and its function as a regulator of mRNA
splicing.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The WW domain-containing PQBP1 (polyglutamine tract-
binding protein 1) gene encodes a protein that regulates mRNA
processing and RNA polymerase II-driven transcription [1–5]. The
PQBP1 gene is highly conserved in evolution and its orthologs in
plants, worms and mammals share a high degree of sequence sim-
ilarity. In mammals, the PQBP1 gene is widely expressed, but its
transcript is enriched in the brain [6]. Originally, the PQBP1 protein
was identiﬁed as a protein partner of poly-glutamine-(poly-Q)-
containing proteins, including huntingtin, ataxin-1 and neuronal
transcription factor Brn-2. Mutations in the PQBP1 gene were
reported in several X chromosome-linked intellectual disability
(XLID) disorders, such as Renpenning, Sutherland-Haan, Hamel,
Porteous, and Golabi-Ito-Hall (GIH) syndromes [7,8]. Interestingly,
although caused by different mutations that affect the coding
sequence of the PQBP1 gene – frame shifts that result in truncated
protein products or a missense point mutation – these syndromes
share similar clinical features [7]. In addition to severe intellectualchemical Societies. Published by E
Transduction and Proteomic
anville, PA 17821, USA. Fax:
).disability, the patients also have a lean body, short stature, small
head, and are frequently diagnosed with cardiac abnormalities
[9,10]. The missense mutation in the GIH syndrome maps within
a functional region of the PQBP1 protein known as theWWdomain
(Fig. 1) [8,11–13]. In contrast to other mutations reported for
PQBP1, the genetic lesion of GIH syndrome does not affect the size
of the mutated protein, which normally migrates on SDS–PAGE as a
singlet of 38 kDa [14].
The WW domain is one of the smallest protein modules medi-
ating speciﬁc protein–protein interactions with short proline-rich
or proline-containing motifs [11–13]. The WW domain mutation
implicated in the GIH syndrome replaces the conserved tyrosine
(Y) at position 65 within the aromatic core of the domain to
cysteine (C), which is a chemically signiﬁcant change to the protein
that we would like to discuss here in detail [14].
Recently, we have documented that the binding of the Y65C
mutant of PQBP1 protein to its cognate ligand, WBP11 (also known
as SIPP1), which regulates mRNA processing, was abrogated com-
pared to that of the control wild-type protein [14]. More impor-
tantly, we have veriﬁed that in lymphoblasts derived from a GIH
patient, the complex between the endogenous PQBP1 and endoge-
nous WBP11 proteins was compromised compared with the intact
complex between these two proteins found in lymphoblasts de-
rived from a normal individual who was matched for race andlsevier B.V. All rights reserved.
Fig. 1. Schematic of the organization of the PQBP1 protein. PQBP1 contains only one
discernable modular domain, the WW domain located at the N-(amino)-terminus.
The causative Y-C PQBP1 mutation of the GIH syndrome is located within the
middle of the WW domain sequence and it is indicated with a red arrow. There are
multiple copies of three distinct amino acid repeats found in PQBP1: ﬁve
consecutive copies of DRXH(D/E)KX and ten copies of (D/E)R, which occur
consecutively in repeats of three and seven separated by a small stretch of
intervening amino acids. At the C-(carboxy)-terminal region there is a stretch of
highly conserved amino acids – GPLFQQRPYPSPG –, which are identical among
PQBP1 proteins of man (Homo sapiens), a sweet water polyp (Hydra magnipapilata)
and a small ﬂowering plant (Arabidopsis thaliana). We indicate the relative location
of this sequence as a green box with CM, after ‘‘conserved motif’’. An indentation on
the box is to suggest a possibility that the CMmotif interacts with the WW domain,
shown as a gray triangle.
Fig. 2. Amino acid sequence alignment of the human family of WW domains. Alignme
domain of PQBP1. Highly conserved amino acid residues across the entire family of WW d
PQBP1 are indicated by vertical arrows. Cysteines are in bold font.
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porter gene construct that monitors efﬁciency of mRNA splicing,
we have shown that the missense mutation in the PQBP1 WW do-
main resulted in a substantial decrease in pre-mRNA splicing [14].
2. Y65 of the WW domain of PQBP1 is conserved among the
family of WW domains
In an effort to understand the importance of tyrosine at position
65 (Y65) in the function of PQBP1, we performed amino acid se-
quence alignment of the entire human family of WW domains
(Fig. 2). Our analysis reveals that Y65 is predominantly conserved
across all WW domains and that it is frequently substituted by
its chemical analogue phenylalanine, further implicating its central
role in the function of WW domains. In addition to Y65, a number
of other residues in the WW domain of PQBP1 are also predomi-
nantly conserved across the entire human family of WW domains.nt is divided into two columns for clarity and each column is headed by the WW
omains are colored red and green, and the equivalent residues in theWW domain of
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and 75 (W52 and W75), an asparagine at position 67 (N67) and a
proline at position 78 (P78). It is notable that while W52 is substi-
tuted by tyrosine in only a few WW domains, W75 displays more
versatility and is replaced by amino acids as diverse as tyrosine,
phenylalanine, isoleucine, glutamine and also cysteine. In a man-
ner akin to the structural versatility of W75, the N67 residue can
also be replaced by amino acids as diverse as aspartate, serine,
tyrosine and histidine. In contrast, WW domains appear to have
an obligate requirement for P78 as it is only absent from the
WW2 domain of ARHGAP27 GTPase. The highly conserved nature
of W52, Y65, N67, W75 and P78 residues in PQBP1 across the en-
tire family of WW domains and their key role in the structural
and functional integrity of WW domains is further corroborated
by site-directed mutagenesis studies on the WW domain of Pin1
[15]. The mutagenesis of the WW domain of Pin1 revealed that
W52, N67, Y65 and P78 form a hydrophobic core of the domain,
which may be important in stabilizing the structure [15].
3. Y65C PQBP1 mutant and intramolecular disulﬁde bonds
In order to gain better insight about the effect of Y65C mutation
on theWW domain fold, we generated 3D atomic models of wt and
Y65C-mutant WW domains of PQBP1 (Fig. 3). As discussed in our
recent study, the hydrophobic core that is located beneath the li-
gand-binding pocket of the wt WW domain is composed of a
highly conserved quartet of hydrophobic residues W52, Y65, N67
and P78 (and perhaps to a lesser extent by W75). While Y65 con-
stitutes a key component of the hydrophobic core within the wild
type domain, the placement of cysteine at this position within the
Y65C-mutant WW domain may not only result in the collapse of
the triple-stranded b-sheet ‘‘roof’’ supporting the ligand-binding
‘‘cradle’’ [16,17], but under oxidative conditions, the formation of
an intramolecular disulﬁde bond between C60 and C65 residues
within the Y65C-mutant WW domain may also be favored
(Fig. 4). This scenario is conceivable due to the inherent ﬂexibility
of the b1-b2 loop allowing it to curve away from the ligand-binding










Fig. 3. 3D atomic models of wild type (A) and Y65C-mutant (B) WW domains of human
intervening loops in gray. The sidechains of residues W52, Y65/C65, N67, W75 and P78bring the C60 and C65 residues in close proximity and thereby
drive their covalent linkage via a disulﬁde bond. As we have shown
recently in an in vitro assay, the binding of Y65C-mutant WW do-
main to its cognate peptide ligands is indeed compromised, but
perhaps not as dramatically as would be expected from the
replacement of a conserved tyrosine with a cysteine within its
hydrophobic core. This salient observation argues in favor of an
alternative mechanism by which the Y65C mutation could lead
to loss-of-function in PQBP1. Given that the in vitro binding stud-
ies, which we recently reported, were conducted under reducing
conditions in the presence of a reducing agent, 5 mM b-mercap-
toethanol [14], it is thus conceivable that the Y65C-mutant WW
domain may behave differently toward its cognate ligands within
the milieu of the cell, than in an in vitro binding assay. Thus, under
non-reducing conditions in response to cellular oxidative stress, for
instance, it is conceivable that the Y65C-mutant WW domain may
undergo intramolecular disulﬁde bond formation as proposed
above. Accordingly, such intramolecular covalent modiﬁcation
would destroy the ‘‘cradle’’ optimized for ligand binding and the
resulting Y65C-mutant domain would not be expected to bind to
its cognate ligands in a physiologically-relevant manner, leading
to loss-of-function in PQBP1, as we observed in co-immunoprecip-
itation assays performed on full length proteins expressed in cul-
tured cells. It is also important to note that C60 occupies a
unique position in the WW domain of PQBP1 and is largely absent
from other WW domains. Moreover, it is intriguing that the posi-
tion of C60 in the WW domain of PQBP1 is either absent in other
WW domains or substituted for by other amino acids, with the
exception of cysteine (Fig. 2). Of particular interest is the observa-
tion that the occurrence of more than one cysteine in the WW do-
mains is a rare event. Of 100 human WW domains, only four
contain more than one cysteine. These include the WW domains
of ARHGAP9, CEP164, MLH3 and PLEKHA2 (Fig. 2). Notably, these
cysteine residues are located in the following areas: within the
b2 and b3 strands (ARHGAP9), the b1 strand and the C-terminus
following the b3 strand (CEP164), within the N-terminus preceding
the b1 strand (MLH3), and within the b1-b2 loop and b3 strand










PQBP1. The triple-stranded b-sheet of the WW domains is shown in blue and the
that constitute the hydrophobic core of the domains are colored red.
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domain structure in distinct manners and may modulate their
function via distinct mechanisms. Although the presence of more
than one cysteine within a protein opens up the possibility of intra-
molecular disulﬁde bond formation, it should be noted that this re-
mains an unlikely scenario in the case of WW domains of
ARHGAP9, CEP164 and PLEKHA2 proteins on structural grounds.
Thus, unlike the Y65C-mutant WW domain of PQBP1, the cysteine
residues are either located within one of the three rigid b-strands
or away from the ﬂexible b1-b2 loop in the WW domains of ARH-
GAP9, CEP164 and PLEKHA2. Taken together, it seems that the
Y65C mutation may predispose the WW domain of PQBP1 to
loss-of-function via the formation of an intramolecular disulﬁde
bond. However, it is important to mention that in some cases in-
tra-molecular disulﬁde bond formation could lead to a gain of pro-
tein function, as exempliﬁed by the bridge between cysteines 377
and 330 in Cdc25C phosphatase, which results in enhanced binding
to 14-3-3 protein and the cytoplasmic sequestration of the protein
[18]. Fittingly, in our in vitro binding studies, we did observe a
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Fig. 4. A hypothetical model for the loss-of-function in the Y65C mutant form of
human PQBP1 in Golabi-Ito-Hall syndrome. Under oxidative conditions, the
formation of an intra-molecular disulﬁde bond between C60 and C65 residues
within the Y65C-mutant WW domain may be favoured. This scenario is conceivable
due to the inherent ﬂexibility of the b1-b2 loop, allowing it to curve away from the
ligand-binding ‘‘cradle’’ toward the hydrophobic core of the WW domain, so as to
bring the C60 and C65 residues in close proximity and thereby drive their covalent
linkage via an S–S bond. Note that the S–S bond between the sidechain SG atoms of
C60 and C65 residues is omitted for clarity.Y65C PQBP1 WW domain compared to the wild type control.
Therefore, it is possible, that in the network or systems view, the
Y65C mutations may result in both loss and gain of function
changes that in concert deregulate mRNA processing.4. Y65C PQBP1 regulation via oxidation
Although in general, proteins that signal in the cytoplasm are
embedded in a reducing environment, the reversible oxidation of
cysteines of cytoplasmic proteins is a well-established regulatory
mechanism for various signaling proteins, including protein–tyro-
sine phosphatases [19]. The general cellular redox state and the
extracellular-ligand stimulated production of reactive oxygen or
reactive nitrogen species (ROS or RNS) affects oxidation of cyste-
ines in proteins, in a reversible manner. Reaction of H2O2 oxidizes
cysteine thiols at ﬁrst to sulfenic acid (SOH), and at higher concen-
trations of the oxidant, to sulﬁnic (SO2H) or sulfonic acid (SO3H)
derivatives [19]. The sulfenic acid (SOH) derivative of C65 of PQBP1
could form sulfenylamides by reaction with other amino acids of
the PQBP1 that are located in the proximity of the WW domain,
in addition to forming an intra-molecular disulﬁde bridge with
C60. Interestingly, the wt PQBP1 protein does not contain any
other cysteine residues except for the WW domain-located C60.
We cannot exclude other possibilities by which oxidation of C65
could regulate the function of PQBP1 protein. The sulﬁnic (SO2H) or
sulfonic acid (SO3H) derivatives of C65 in PQBP1 may lead to con-
formational changes that also render the domain inactive in terms
of ligand binding. Moreover, the cysteine thiols in a local environ-
ment with pKa below 6 could form a reactive thiolate anion that is
permissive for posttranslational modiﬁcations such as phosphory-
lation, glutathionylation or even adduct formation with other
endogenous electrophilic molecules [19]. Such modiﬁcations could
also render the mutated WW domain inactive in terms of ligand
binding and signaling of the PQBP1 complex in mRNA processing.5. Concluding remarks
The atomic details of the Y65C lesion of the PQBP1 protein will
hopefully come soon from crystal structures of the wild type and
mutant proteins. Apart from the intrinsic changes that the muta-
tion causes to the WW domain itself, it will be very important to
see the relative location of the carboxy-terminal tail of the protein
with its well-conserved motif (CM) (Fig. 1). Since most of the
PQBP1 mutations that result in XLID syndromes have the car-
boxy-terminal region of the protein missing, including the very
CM sequence, we presume that somehow the WW domain and
the CM region collaborate together to regulate mRNA splicing.
Apart from X-ray crystallography, two other approaches repre-
sent attractive ways to study the effect of the Y65C mutation on
the molecular architecture of the PQBP1 protein. These are protein
folding assays in the periplasm of bacteria [20] and atomic force
microscopy [21]. Both of these approaches are able to interrogate
the PQBP1–Y65C mutant and wild type proteins under reducing
and non-reducing conditions. These two approaches could quickly
validate several regulatory scenarios proposed here.
In sum, our recent studies on PQBP1 and various plausible
mechanisms discussed here for the inactivation of PQBP1 provide
the framework for conducting future studies to unlock the molec-
ular basis of XILD disorders at atomic level with important conse-
quences on the rational design of therapeutic approaches.
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